-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ranibizumab in Retinopathy Of Prematurity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ranibizumab in Retinopathy Of Prematurity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ranibizumab in Retinopathy Of Prematurity Drug Details:Ranibizumab (Lucentis, Patizra) is a humanized...
-
Product Insights
IGO/ Wyloo Metals – Kwinana Integrated Battery Materials Facility – Western Australia
Equip yourself with the essential tools needed to make informed and profitable decisions with our IGO/ Wyloo Metals - Kwinana Integrated Battery Materials Facility - Western Australia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Sector Analysis
Australia Copper Mining Market by Reserves and Production, Assets and Projects, Fiscal Regime with Taxes, Royalties and Forecast to 2030
Australia Copper Mining Market Report Overview Australia has the world’s second-largest copper reserves after Chile, accounting for more than 10% share in the global copper reserves. In 2023, copper production in the country is expected to grow supported by output from the existing mines including Olympic Dam, Cadia, Carrapateena and Boddington. Additionally, Aeris Resources’ Avoca Tank and IGO’s Savannah North are expected to begin operations in 2023. The reserves are predominantly located at the Olympic Dam Mine in South Australia...
-
Company Profile
IGO Ltd – Company Profile
IGO Ltd (IGO) is a mining company that focused acquisition, exploration, production and development of gold, copper, nickel, zinc, cobalt and silver deposits properties. The company's own interests in Nova ni-cu-co operation and indirect and non-operated interest in the Greenbushes lithium mine and Kwinana lithium hydroxide refinery. Its discovery portfolio also comprises belt-scale greenfield opportunities in the northern territory at the expanded Lake Mackay project and Raptor project and a frontier project in Eastern Greenland. IGO is headquartered in Perth,...
Add to Basket -
Company Profile
Prodigy Gold NL – Company Profile
Prodigy Gold NL (Prodigy Gold) is a mining company. It is involved in exploration of gold, zinc, lead and copper. The company’s projects include the Buccaneer project, Hyperion project, Old Pirate project, Tobruk and Monza JV project, Lake Mackay Project, and North Arunta Project. The company operates Lake Mackay Project in a joint venture agreement with Independence Group (IGO) and operates North Arunta Project in a joint venture agreement with Gladiator Resources. Tobruk and Monza JV project carries out the...
Add to Basket -
Product Insights
Net Present Value Model: Byooviz
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Byooviz Drug Details Ranibizumab (Byooviz, ranibizumab-nuna)...
-
Product Insights
Net Present Value Model: Susvimo
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Susvimo Drug Details Ranibizumab (Susvimo) is...
-
Product Insights
Net Present Value Model: Ranibizumab biosimilar
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Ranibizumab biosimilar Drug Details Ranibizumab (Ongavia,...
-
Product Insights
Net Present Value Model: Lucentis
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Lucentis Drug Details Ranibizumab (Lucentis, Patizra)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ranibizumab SR
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ranibizumab SR Drug Details Ranibizumab (Susvimo) is a humanized monoclonal antibody fragment and a...